Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amarin

- PMLiVE

England’s Cancer Drugs Fund: Naughty or NICE?

The decision to extend the CDF raises questions on the future of cancer drug access on the NHS

- PMLiVE

Alexion convinces NICE of Soliris’ value

But recommendation of the expensive 'ultra orphan' drug' comes with conditions

- PMLiVE

Sanofi/Regeneron’s alirocumab ‘cuts cardiovascular events’

Data presented at ESC Congress demonstrates lower rates of cardiac death, stroke and more

- PMLiVE

England’s Cancer Drugs Fund receives new funding boost

Gains an extra £160m to pay for drugs not recommended by NICE

- PMLiVE

NICE wants more data on Boehringer’s Jardiance

Pharma company needs to demonstrate cost-effectiveness of its diabetes drug

Biogen Idec building

Final NICE backing for Biogen Idec’s Tecfidera

Oral multiple sclerosis is cleared for NHS use in England

- PMLiVE

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

Easier access to medicines in the UK?

Cutting through the NICE value-based assessment consultation to find out what’s at stake

- PMLiVE

NICE backs Celgene’s Revlimid in bone marrow disorder

Recommends that drug can be used on NHS to treat myelodysplastic syndromes

- PMLiVE

NICE backs Gilead’s Sovaldi in hepatitis C

But health watchdog denies earlier use of Janssen’s Zytiga

Novartis building

Novartis will file heart failure drug before year-end

New data reinforces view that LCZ696 can reduce cardiovascular deaths

National Institute for Health and Care Excellence NICE logo

Public advises NICE on value of care

Citizens Council publishes report on the way health and social care resources are allocated in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links